Anti-SARS-CoV-2 (B.1.617.2) Antibody IgG Titer Serologic Assay Kit (Spike RBD)

Spike RBD

Multiple variants of SARS-CoV-2 are circulating globally and posting new challenges to human health. The variant B.1.1.7 identified in the United Kingdom (UK) carries a large number of mutations and is reported to spread more easily and quickly than other variants. The variant B.1.351 identified in South Africa ，P.1 identified in Brazil and B.1.617.2 in India show evidence of increased transmissibility and resistance to established immunity. A common mutation identified in the U.K, South African and Brazilian variants is N501Y, and the mutation identified in B.1.617.2 is T478K, which resides on the receptor-binding domain (RBD) of SARS-CoV-2 spike protein. To evaluate the impacts of the new variants, a rapid and effective assay kit detecting the levels of antibody against the mutant is in urgent need.

This Kit is developed for qualitative detection or titer measurement of Anti-SARS-CoV-2 (B.1.617.2) antibody IgG (Spike RBD) in human serum.